#United States #New York #Gross Law Firm #Lead Plaintiff #Skye Bioscience

Skye Bioscience Shareholders: Important Notice

Overview

The Gross Law Firm has issued an advisory to shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE), encouraging them to reach out before January 16, 2026. This notice is crucial for investors who purchased shares during a specified class period as they may have rights related to potential misrepresentations from the company.

Class Period Details

The timeframe in question spans from November 4, 2024, to October 3, 2025. During this period, shareholders may have experienced losses due to alleged misleading statements by the company regarding their lead product candidate, nimacimab. According to the complaint, Skye Bioscience's management is accused of exaggerating the effectiveness and prospects of nimacimab, leading investors to make decisions based on inaccurate information.

Allegations Against Skye Bioscience

Shareholders should be aware that the allegations detail the company issued statements that were materially false and misleading. Notably, these claims included:
1. The efficacy of nimacimab was overstated compared to what was communicated to investors.
2. The clinical and regulatory prospects of nimacimab were inaccurately presented, exaggerating the commercial gains expected from the product.

These misrepresentations caused an artificial inflation in the company's stock price, which eventually led to financial losses for the investors when the true effectiveness of the product was revealed.

Next Steps for Shareholders

It is important for shareholders who purchased stock in SKYE during the aforementioned period to register for the class action lawsuit as soon as possible. By doing so, investors will also gain access to a portfolio monitoring software that provides regular updates on the status of the case.

To enroll, visit the registration link provided by The Gross Law Firm, ensuring all relevant information is submitted before the deadline. Participation in this class action does not obligate investors financially; there are no costs associated with being a part of this case.

Why Choose The Gross Law Firm?

The Gross Law Firm boasts a national reputation in handling class action lawsuits that seek justice for investors. Their commitment lies in holding corporations accountable for deceitful practices, ensuring stakeholders receive due justice and recovery for the losses incurred due to unscrupulous activities by companies. The firm emphasizes the necessity for companies to adhere to ethical practices and responsible governance.

Investors facing difficulties due to damaged stock value from misleading statements are encouraged to act quickly. This opportunity aims to recover losses purportedly suffered during the class period mentioned, offering a potential remedy against corporate wrongdoing.

For assistance, shareholders can contact The Gross Law Firm directly:

• - Address: 15 West 38th Street, 12th floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

Conclusion

In conclusion, all shareholders of Skye Bioscience, Inc. should carefully consider their position and take necessary steps to protect their rights. With the deadline approaching, proactive engagement is crucial for those affected. Legal representation could provide the necessary support needed to navigate this complex issue and secure rightful compensation for misrepresentations impacting their investments.

Don't wait until it's too late—act before the January deadline.